SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CECONI, Claudio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.225
AS - Asia 10.395
EU - Europa 6.270
SA - Sud America 1.751
Continente sconosciuto - Info sul continente non disponibili 252
AF - Africa 215
OC - Oceania 36
Totale 41.144
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.789
SG - Singapore 3.929
CN - Cina 2.619
IT - Italia 2.133
BR - Brasile 1.369
UA - Ucraina 1.265
HK - Hong Kong 941
VN - Vietnam 874
DE - Germania 712
TR - Turchia 637
GB - Regno Unito 536
FI - Finlandia 432
BD - Bangladesh 389
FR - Francia 314
RU - Federazione Russa 300
SE - Svezia 201
JP - Giappone 198
CA - Canada 180
IN - India 177
MX - Messico 160
AR - Argentina 132
ID - Indonesia 101
IQ - Iraq 80
PL - Polonia 77
ZA - Sudafrica 76
EC - Ecuador 63
PK - Pakistan 59
CO - Colombia 57
ES - Italia 57
MY - Malesia 53
PH - Filippine 51
AT - Austria 47
NL - Olanda 46
UZ - Uzbekistan 41
VE - Venezuela 38
CL - Cile 34
MA - Marocco 33
SA - Arabia Saudita 30
AU - Australia 27
KE - Kenya 24
PY - Paraguay 24
KR - Corea 23
JM - Giamaica 22
AE - Emirati Arabi Uniti 21
TN - Tunisia 21
EG - Egitto 19
GE - Georgia 18
LT - Lituania 18
PE - Perù 18
TH - Thailandia 18
JO - Giordania 16
CR - Costa Rica 13
BE - Belgio 12
NP - Nepal 12
RO - Romania 12
CZ - Repubblica Ceca 11
IE - Irlanda 11
LB - Libano 11
NI - Nicaragua 10
PT - Portogallo 10
TW - Taiwan 10
AL - Albania 9
CH - Svizzera 9
GT - Guatemala 9
HN - Honduras 9
PS - Palestinian Territory 9
TT - Trinidad e Tobago 9
DZ - Algeria 8
IL - Israele 8
IR - Iran 8
KZ - Kazakistan 8
OM - Oman 8
BG - Bulgaria 7
BO - Bolivia 7
GR - Grecia 7
KG - Kirghizistan 7
SN - Senegal 7
UY - Uruguay 7
AM - Armenia 6
MD - Moldavia 6
MN - Mongolia 6
NZ - Nuova Zelanda 6
RS - Serbia 6
BH - Bahrain 5
BS - Bahamas 5
BY - Bielorussia 5
ET - Etiopia 5
EU - Europa 5
KW - Kuwait 5
AO - Angola 4
AZ - Azerbaigian 4
DO - Repubblica Dominicana 4
HR - Croazia 4
LV - Lettonia 4
MM - Myanmar 4
PA - Panama 4
BA - Bosnia-Erzegovina 3
HU - Ungheria 3
LY - Libia 3
NO - Norvegia 3
Totale 40.847
Salva come PNG Salva come JPEG
Città #
Singapore 2.448
Woodbridge 2.378
Fairfield 2.368
Ashburn 2.090
Houston 1.370
Jacksonville 1.352
Seattle 994
Hong Kong 925
San Jose 898
Chandler 887
Ann Arbor 886
Wilmington 810
Cambridge 795
Santa Clara 748
Beijing 599
Dallas 551
Izmir 433
Nanjing 410
Princeton 349
Ho Chi Minh City 306
New York 246
Boardman 232
San Diego 232
Los Angeles 223
Milan 221
Council Bluffs 220
Lauterbourg 209
Hanoi 197
Tokyo 182
Rome 152
Helsinki 149
Shenyang 135
Nanchang 119
Moscow 112
São Paulo 104
Mexico City 103
Hefei 101
Hebei 81
Chicago 79
San Mateo 77
Changsha 75
Falls Church 68
Ferrara 68
Warsaw 68
Jiaxing 67
London 67
Tianjin 67
Naples 64
Toronto 60
Jinan 58
Shanghai 58
Munich 52
Zhengzhou 48
Mountain View 47
Verona 46
Montreal 42
Jakarta 40
Ningbo 40
Rio de Janeiro 40
Bremen 38
Da Nang 38
Tashkent 38
Brooklyn 37
Redwood City 37
Taizhou 37
Atlanta 36
Frankfurt am Main 35
Philadelphia 35
Buffalo 34
Johannesburg 34
The Dalles 34
Haiphong 32
Phoenix 32
Orem 29
Columbus 28
Kuala Lumpur 28
Chennai 27
Guangzhou 27
Norwalk 27
Turin 27
Baghdad 26
Addison 25
Tappahannock 25
Washington 25
Napoli 24
Kunming 23
San Francisco 23
Stockholm 23
Curitiba 22
Hangzhou 22
Indiana 22
Belo Horizonte 21
Biên Hòa 21
Bologna 21
Campinas 21
Denver 21
Guarulhos 21
Porto Alegre 21
Bari 20
Brasília 20
Totale 26.983
Salva come PNG Salva come JPEG
Nome #
IL METABOLISMO DEL MIOCARDIO ISCHEMICO IBERNATO E STORDITO: DIFFERENZA TRA NECROSI E APOPTOSI 1.848
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 354
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC 313
2015 ESC Guidelines for the diagnosis and management of pericardial diseases The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) 293
Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review 289
Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management 276
Uric acid and coronary artery disease: An elusive link deserving further attention 258
Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study 253
Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review 252
Abnormalities of Left Ventricular Function in Asymptomatic Patients with Systemic Sclerosis Using Doppler Measures of Myocardial Strain 247
A way forward to the elimination of conflict of interest for experts involved in regulatory medicine and guidelines 239
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes 238
2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure [Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica] 238
Effects of temperature on myocardial calcium homeostasis and mitochondrial function during ischemia and reperfusion 237
Third Universal Definition of Myocardial Infarction 234
Incremental exercise using progressive versus constant pedaling rates: A study in cardlac patients 231
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals 229
Third Universal Definition of Myocardial Infarction 226
ACE inhibition modulates endothelial apoptosis and renewal via endothelial progenitor cells in patients with acute coronary syndromes (Am Journal of Cardiovasc Drugs (2011) 11:3 (189-98)) 224
Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL 221
Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis 219
Enhanced expression and activity of xanthine oxidoreductase in the failing heart. 218
The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: Study protocol for a randomized controlled trial 217
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. 216
Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention 200
Is stunning an important component of preconditioning? 199
Advanced glycation end products and its soluble receptor (sRAGE) are increased in chronic heart failure but not in chronic obstructive pulmonary disease. 199
Prolonged propionyl-L-carnitine pre-treatment of rabbit: Biochemical, hemodynamic and electrophysiological effects on myocardium 197
ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study 196
Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) 195
Guidelines on myocardial revascularization 194
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). 194
Multiparametric flow cytometric characterization of circulating stem cell subsets in patients with myocardial infarction: correlation with clinical and biological data 190
The ACE-inhibitor Perindoprilat has high selectivity for bradykinin binding sites of human somatic ACE 189
Neglected COPD and chronic comorbidities in elderly patients with chronic heart failure 189
[Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI] 187
In vitro administration of ergothioneine failed to protect isolated ischaemic and reperfused rabbit heart 187
Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: The cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study 185
ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). 185
Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology 184
[Heart failure: an endothelial disorder?] 183
Activation of the neuroendocrine response in heart failure: adaptive or maladaptive process? 183
Reduction of oxidative stress by carvedilol: Role in maintenance of ischaemic myocardium viability 181
Oxygen free radicals and myocardial damage: Protective role of thiol-containing agents 181
Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice 181
Neuroendocrine Control of the Cardiovascular System in Heart Failure 181
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD 181
Occurrence of oxidative stress during reperfusion of the human heart 179
Bradykinin and coronary artery disease 179
Heart rate reduction by pharmacological If current inhibition 178
Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies 177
Right heart failure chronically stimulates heat shock protein 72 in heart and liver but not in other tissues. 177
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology 177
The heart rate story 177
Secondary Prevention of CAD with ACE Inhibitors: A Struggle Between Life and Death of the Endothelium 176
[Comparative protective effect of gallopamil in myocardial ischemia and reperfusion] 176
Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE 176
Postinfarction Left Ventricular Free Wall Rupture: Original Management and Surgical Technique 175
[The double face of oxygen. An introduction to cardiac pathology caused by oxidation injury] 175
Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression 175
Myocardial damage during ischaemia and reperfusion 174
Traditional and new composite endpoints in heart failure clinical trials: Facilitating comprehensive efficacy assessments and improving trial efficiency 174
Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy 174
Effect of D-600 on ischemic and reperfused rabbit myocardium: relation with timing and modality of administration. 173
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation 173
Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA) 172
The prospective impact of chronic obstructive pulmonary disease on short-term prognosis of patients with chronic heart failure 172
Time course of human atrial natriuretic factor release during cardiopulmonary bypass in mitral valve and coronary artery diseased patients 169
Effect of superoxide generation on rat heart mitochondrial pyruvate utilization 168
Pathophysiological role of heart rate: from ischaemia to left ventricular dysfunction 168
The effect of propionyl-L-carnitine on the ischemic and reperfused intact myocardium and on their derived mitochondria 167
Third universal definition of myocardial infarction 167
Mechanisms of remodelling - A question of life (stem cell production) and death (myocyte apoptosis) - 167
Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease 167
Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes 166
Different outcomes of the reperfused myocardium: insights into the comments of stunning and hibernation. 165
Specific properties and effect of perindopril in controlling the renin-angiotensin system 165
Chromogranin A in heart failure - A novel neurohumoral factor and a predictor for mortality 165
ESC Guidelines for the management of grown-up congenital heart disease (new version 2010) 165
Selective and specific I f inhibition with ivabradine: New perspectives for the treatment of cardiovascular disease 165
Oxygen Free Radicals in Shock 165
Oxidative stress during myocardial ischaemia and heart failure 165
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease 165
New insights on myocardial pyridine nucleotides and thiol redox state in ischemia and reperfusion damage 164
Skeletal muscle abnormalities in rats with experimentally induced heart hypertrophy and failure 164
Tumor necrosis factor in congestive heart failure: a mechanism of disease for the new millennium? 164
Interleukin-6, but not pentraxin 3, predicts adverse clinical outcomes on short-term prognosis of patients with incipient heart failure 164
Studio dei progenitori emopoietici circolanti in pazienti con infarto del miocardio 164
Different sites of action of diltiazem, nifedipine and verapamil on myocardial, coronary and aortic muscle 163
Oltre la dissincronia quali fattori determinano la risposta alla terapia di resincronizzazione cardiaca? 163
Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina 163
Cellule staminali circolanti in pazienti con infarto miocardico 163
Angiotensin II overproduction: enemy of the vessel wall 163
Evidence against malondialdehyde bound to cellular constituents in phospholipid peroxidation 163
Ischemic Heart Disease. 130 Questions & Answers 162
Left ventricular dysfunction due to stunning and hibernation in patients 162
Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts 162
Metabolic changes during post-ischaemic reperfusion. 161
Mechanical vs. electrical dyssynchrony for CRTselection in patients with HF 161
Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction 161
Totale 20.846
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.895
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 7.430
Totale 185.325
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.914 0 374 306 82 107 137 167 151 100 187 262 1.041
2022/20232.315 277 29 78 259 391 382 52 243 315 24 152 113
2023/20241.176 178 166 77 50 66 130 48 31 18 64 56 292
2024/20254.108 83 106 341 104 527 279 138 304 693 545 480 508
2025/202612.764 1.001 540 1.422 1.663 1.420 839 1.212 825 1.318 1.452 661 411
2026/20271.047 628 419 0 0 0 0 0 0 0 0 0 0
Totale 41.144